Protagonist Therapeutics Director Executes Option and Sells $2.52M in Stock After FDA Nod for Icotyde
Protagonist Therapeutics director Harold E. Selick exercised options to buy 24,000 shares at $12.88 and sold those shares along with an additional 24,000 shares on March 26, 2026, generating proceeds of $2.52 million from the stock sale and $309,120 tied to the option exercise. The share transactions occurred with the stock trading near its 52-week…